- Home
- VINP vs ARCT Comparison
VINP vs ARCT Comparison
Compare VINP & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VINP | ARCT |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 807.6M | 194.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | VINP | ARCT |
|---|---|---|
| Price | $12.90 | $6.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $13.50 | ★ $38.67 |
| AVG Volume (30 Days) | 43.6K | ★ 829.5K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | ★ 4.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $180,689,571.00 | $97,601,000.00 |
| Revenue This Year | $67.12 | N/A |
| Revenue Next Year | $15.14 | N/A |
| P/E Ratio | $25.69 | ★ N/A |
| Revenue Growth | ★ 100.47 | N/A |
| 52 Week Low | $8.66 | $5.85 |
| 52 Week High | $13.25 | $24.17 |
Technical Indicators
Market Signals| Indicator | VINP | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 61.88 | 35.49 |
| Support Level | $12.04 | $6.38 |
| Resistance Level | $13.25 | $7.76 |
| Average True Range (ATR) | 0.32 | 0.43 |
| MACD | 0.01 | 0.20 |
| Stochastic Oscillator | 71.14 | 24.87 |
Price Performance
Historical ComparisonAbout VINP Vinci Partners Investments Ltd.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.